R CONTEE S Pr A YUAN LAW OFFICES 北京 BEIJING·上海 SHANGHAI·深圳 SHENZHEN·香港 HONGKONG·广州 GUANGZHOU·西安 XI`AN 致:派斯双林生物制药股份有限公司 北京市嘉源律师事务所 关于派斯双林生物制药股份有限公司 2023 年年度股东大会的 北京市嘉源律师事务所 关于派斯双林生物制药股份有限公司 2023 年年度股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 法律意见书 嘉源(2024)-04-379 北京市嘉源律师事务所(以下简称"本所")接受派斯双林生物制药股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")、《上市公司股东大会规则》(以下简称"《股东大会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《派斯双林生物制药股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司2023年年度股东大会(以下简称"本次股东大 会"）进行见证,并依法出具本法律意见书。 为出具本法律意见书,本 ...

派斯双林生物制药股份有限公司 2023年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 证券代码：000403 证券简称：派林生物 公告编号：2024-034 一、会议召开和出席情况 （一）会议召开情况： 1、召开时间： （1）现场会议时间：2024 年 5 月 21 日（星期二）下午 14:30 （2）网络投票时间：其中，通过深圳证券交易所交易系统网络投票的时间为： 2024 年 5 月 21 日上午 9:15—9:25；9:30—11:30，下午 1:00—3:00；通过深圳证券交 易所互联网投票系统网络投票时间为：2024 年 5 月 21 日上午 9:15 至下午 15:00 期 间的任意时间。 2、现场会议地点：上海市浦东新区海阳西路 551 号上海前滩香格里拉三楼梅桂 柏厅 3、会议召开方式：现场投票与网络投票相结合方式 4、会议召集人：公司董事会 本次股东大会的议案全部获得通过，未出现否决议案的情形。 本次股东大会不涉及变更前次股东大会已通过的决议。 5、会议主持人：董事长李昊先生 6、本次会议的召开符合《公司 ...

证券代码：000403 证券简称：派林生物 公告编号：2024-033 派斯双林生物制药股份有限公司 关于持股 5%以上股东股份减持计划实施完成的公告 股东杨峰女士保证向本公司提供的信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 本公司及董事会全体成员保证信息披露内容与信息披露义务人提供的信息一致。 派斯双林生物制药股份有限公司（以下简称"公司"）于 2024 年 2 月 29 日披 露了《关于持股 5%以上股东减持股份计划的预披露公告》（公告编号：2024-005）， 公司股东杨峰女士因缴纳税费等资金需求，拟以集中竞价交易或大宗交易方式减持 公司股份不超过 6,000,000 股（含）。 公司于近日收到杨峰女士出具的《关于股份减持计划实施完成的告知函》，截至 公告日杨峰女士股份减持计划已实施完成。根据中国证监会《上市公司股东、董监高 减持股份的若干规定》《深圳证券交易所上市公司股东及董事、监事、高级管理人员 减持股份实施细则》等相关规定，现将实施结果公告如下： 1、股东减持股份情况 2、股东减持前后持股情况 | 股东名称 | | 本次减持前持有股份 | | 本次减持后持有股份 | | ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's performance in 2023 met expectations, with a revenue of 2.33 billion yuan, a year-on-year decrease of 3.2%, and a net profit attributable to shareholders of 610 million yuan, a year-on-year increase of 4.3% [2] - In Q1 2024, the company achieved a revenue of 440 million yuan, a year-on-year increase of 67%, and a net profit attributable to shareholders of 120 million yuan, a year-on-year increase of 116.3% [2] - The company is expected to experience a growth inflection point in plasma collection due to the establishment of new plasma stations [2] Summary by Sections Financial Performance - In 2023, the company's quarterly revenues were 260 million, 450 million, 670 million, and 950 million yuan respectively, showing a significant recovery in the latter half of the year [2] - The overall gross profit margin for 2023 was 51.5%, with a net profit margin of 26.3%, reflecting a year-on-year increase of 1.9 percentage points [2] Growth Drivers - The company has received approval for eight new plasma collection stations since August 2022, which is expected to accelerate plasma collection in 2024 [2] - The estimated net profit for 2024-2026 is projected to be 780 million, 890 million, and 1.02 billion yuan respectively, with corresponding valuations of 28x, 25x, and 21x [2] Market Position - The company has a total market capitalization of 21.84 billion yuan and a total asset value of 8.72 billion yuan [5] - The company's earnings per share (EPS) for 2023 is 0.84 yuan, with a projected increase to 1.39 yuan by 2026 [3][10]

地址：鸡东县南华大街南侧，原看守所西侧 证券代码：000403 证券简称：派林生物 公告编号：2024-031 派斯双林生物制药股份有限公司 关于鸡西市东海派斯菲科单采血浆有限公司获得单采血浆许可证 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）全资子公司哈尔滨派斯菲科 生物制药有限公司下属鸡西市东海派斯菲科单采血浆有限公司（以下简称"鸡西浆站"） 收到黑龙江省卫生健康委员会签发的《单采血浆许可证》，现将主要信息公告如下： 机构名称：鸡西市东海派斯菲科单采血浆有限公司 鸡西浆站自本次取得《单采血浆许可证》之日起可正式采浆，鸡西浆站实现采浆有 利于提升公司原料血浆供应能力，有利于提升公司经营业绩，对公司长期发展具有积极 作用。 特此公告。 派斯双林生物制药股份有限公司 董 事 会 二〇二四年五月九日 1 业务项目：采集健康人普通血浆和特免血浆 采浆区域（范围）：鸡西市所辖的区、县及县级市，林口县、绥芬河市、穆棱市和东 宁市 登记号：67748528123000016F2009 有效期：2024 年 5 ...

Investment Rating - The report maintains a "Buy" rating for the company [3]. Core Views - Multiple factors are driving rapid growth in performance, with plasma collection scale reaching the first tier in the industry [2]. - The company achieved a significant increase in revenue and net profit in Q1 2024, with revenue of 4.36 billion yuan, up 67% year-on-year, and net profit of 1.22 billion yuan, up 116.31% year-on-year [1][2]. - The company has a total of 38 plasma collection stations, ranking among the top three in the industry, with a plasma collection volume exceeding 1,200 tons in 2023 [2]. Summary by Sections Financial Performance - In 2023, the company reported revenue of 2.329 billion yuan, a decrease of 3.18% year-on-year, and a net profit of 612 million yuan, an increase of 4.25% year-on-year [1]. - For Q1 2024, the company reported revenue of 4.36 billion yuan, a year-on-year increase of 67%, and a net profit of 1.22 billion yuan, a year-on-year increase of 116.31% [1][2]. Growth Drivers - The rapid growth in performance is attributed to a significant increase in plasma volume, strong sales demand (especially for albumin and immunoglobulin), and deepened operational reforms [2]. - The company is continuously investing in the development of new products, with over 10 products in the research pipeline, which is expected to enhance the comprehensive utilization rate of plasma [2]. Profit Forecast and Valuation - The profit forecast for 2024 and 2025 has been raised to 7.82 billion yuan and 9.34 billion yuan, respectively, reflecting an increase of 5% and 8% from previous estimates [3]. - The projected net profit for 2026 is 10.86 billion yuan, representing a year-on-year growth of 27.71% [3].

[Table_Title] 证券研究报告 业绩快速增长，推动吨浆利润提升和新浆站拓 公司研究 展 [Table_ReportType] 公司点评报告 [Table_ReportDate] 2024年05月01日 [派Ta林bl生e_物Sto（ck0A0n0dR4a0n3k.]SZ） [T事ab件le：_派Su林mm生ar物y]发布2024年一季报，2024Q1公司实现营收4.36亿元，同 投资评级 无 比增长67.00%，实现归母净利润1.22亿元，同比增长116.31%，实现扣 上次评级 无 无 非净利润1.08亿元，同比增长196.85%。公司发布2023年年度报告，2023 年公司实现营收23.29亿元，同比下滑3.18%，实现归母净利润6.12亿元， [唐Ta爱b金le_医Au药th行o业r]首席分析师 同比增长4.25%，实现扣非净利润5.65亿元，同比增长9.08%。根据2023 执业编号：S1500523080002 年利润分配公告，公司向全体股东每10股派发现金红利2元（含税），共 联系电话：19328759065 派发现金1.46亿元。 邮箱：tangaijin@cindasc.com 点评 ...

Investment Rating - The report recommends a "Buy" rating for the company, indicating a positive outlook for its stock performance [7]. Core Insights - The company reported a revenue of 2.329 billion yuan in 2023, a decrease of 3.18%, but a net profit of 612 million yuan, an increase of 4.25%. The first quarter of 2024 showed significant growth with a revenue of 436 million yuan, up 67%, and a net profit of 122 million yuan, up 116.31% [4][5]. - The company has improved its plasma collection, exceeding 1,200 tons in 2023, which is expected to support product growth in 2024. The demand for blood products remains strong, contributing to the company's positive performance [5][6]. - The company is focusing on enhancing efficiency and profitability, with a sales expense ratio of 12.26%, a decrease of 4.35 percentage points, and a net profit margin of 26.26%, an increase of 1.82 percentage points [6]. Financial Projections - The company is projected to achieve net profits of 780 million yuan, 940 million yuan, and 1.1 billion yuan for the years 2024, 2025, and 2026, respectively. Corresponding EPS is expected to be 1.07 yuan, 1.29 yuan, and 1.50 yuan [7][8]. - The projected revenue growth rates for 2024, 2025, and 2026 are 27.54%, 16.19%, and 13.26%, respectively, indicating a strong growth trajectory [8][9].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 34.56 CNY, unchanged from the previous rating [1]. Core Insights - The company has fully restored its plasma collection operations, which is expected to support future growth. The construction of new plasma stations is ongoing, enhancing the company's long-term collection capacity [1]. - The company's performance in 2023 met expectations, with a revenue of 2.329 billion CNY, a decrease of 3.2% year-on-year, and a net profit of 612 million CNY, an increase of 4.3% [1]. - The report forecasts significant growth in 2024, with an expected revenue of 2.804 billion CNY, representing a 20% increase, and a net profit of 774 million CNY, a 26% increase [6][7]. Financial Summary - The company reported a revenue of 2.329 billion CNY in 2023, with a net profit of 612 million CNY. The forecast for 2024 is a revenue of 2.804 billion CNY and a net profit of 774 million CNY [1][6]. - The earnings per share (EPS) for 2023 is projected at 0.84 CNY, increasing to 1.06 CNY in 2024 and 1.28 CNY in 2025 [1][7]. - The company's operating profit margin is expected to improve from 27.9% in 2023 to 30.9% in 2024 [6][7]. Growth Potential - The company is expected to benefit from high demand for blood products, with specific products like immunoglobulin experiencing supply shortages. The overall plasma collection volume is anticipated to continue increasing [1]. - The ongoing construction of new plasma stations is expected to enhance the company's future collection capacity, positioning it to enter the ranks of large-scale blood product companies [1][6].

派斯双林生物制药股份有限公司 2023 年度独立董事述职报告 本人作为派斯双林生物制药股份有限公司（以下简称"公司"）2023 年度的独立董 事，2023 年度，严格按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证 券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》《公司章程》及公司《独立董事工作制度》等有关规定，恪尽职守，勤勉 尽责，充分发挥独立董事的作用，切实维护公司整体利益、维护全体股东尤其是中小股 东合法权益。现将 2023 年度本人履行职责情况述职如下： 一、 基本情况 1．独立董事基本情况 董作军，中国国籍，无境外永久居留权，男，1970年生，博士学位。1992年本科毕 业于中国药科大学医药企业管理专业，2002年硕士毕业于中国药科大学药事管理专业， 2010年博士毕业于中国药科大学社会与管理药学专业。曾任浙江省食品药品监督管理局 副处长等。现任公司独立董事，浙江工业大学讲师，浙江康恩贝制药股份有限公司独立 董事，中翰盛泰生物技术股份有限公司独立董事。 2．关于独立性自查情况 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 ...